You are in: eMedicine Specialties > Ophthalmology > INTRAOCULAR PRESSURE Glaucoma, UnilateralArticle Last Updated: Mar 8, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Ingrid U Scott, MD, MPH, Professor, Department of Ophthalmology and Public Health Sciences, Penn State College of Medicine Ingrid U Scott is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Macula Society, Phi Beta Kappa, and Retina Society Editors: Bradford Shingleton, MD, Assistant Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Martin B Wax, MD, Clinical Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Ophthalmology Research and Development, Head, Ophthalmology Discovery Research, Alcon Labs, Inc; Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri; Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences Author and Editor Disclosure Synonyms and related keywords: open angle, closed angle, vision loss, visual deficit, open-angle glaucoma, episcleral venous pressure, EVP, glaucoma associated with iridocorneal endothelial syndrome, ICE syndrome INTRODUCTIONBackgroundWhile any type of glaucoma can be unilateral, primary open-angle glaucoma, primary angle-closure glaucoma, primary infantile glaucoma, juvenile-onset glaucoma, and pigmentary glaucoma are generally bilateral diseases, the severity of which may be asymmetric in the two eyes. This article reviews glaucoma associated with increased episcleral venous pressure (EVP) and glaucoma associated with iridocorneal endothelial (ICE) syndrome. Several etiologies of unilateral glaucoma are discussed in detail in other articles, including Glaucoma, Pseudoexfoliation; Glaucoma, Uveitic; Glaucoma, Lens-Particle; Glaucoma, Drug-Induced; Glaucoma, Neovascular; Glaucoma, Intraocular Tumors; Glaucoma, Hyphema; Glaucoma, Angle Recession; and Glaucoma, Malignant. PathophysiologyIncreased EVP In the early 1900s, Lauber provided histological evidence that the canal of Schlemm was connected to the episcleral venous network. Aqueous humor drains via the anterior surface of the ciliary body or through the trabecular meshwork, Schlemm canal, collector channels, and, subsequently, aqueous veins. These pathways have been termed unconventional and conventional, respectively. While the unconventional pathway is independent of pressure, outflow via the conventional route is passive and depends largely on the difference between the intraocular pressure (IOP) and EVP; as EVP increases relative to IOP, or as resistance increases, flow decreases. The 3 general pathophysiological mechanisms of increased EVP are arteriovenous anomalies, venous obstruction, and idiopathic. Arteriovenous anomalies associated with increased EVP include carotid-cavernous sinus fistula, orbital varix, Sturge-Weber syndrome, orbital-meningeal shunts, carotid-jugular venous shunts, and intraocular vascular shunts. Venous obstruction may be caused by a retrobulbar tumor, thyroid ophthalmopathy, superior vena cava syndrome, congestive heart failure, thrombosis of the cavernous sinus or orbital vein, vasculitis involving the episcleral or orbital vein, and jugular vein obstruction. ICE syndrome The pathophysiological mechanism underlying ICE syndrome remains unknown. However, the finding of chronic inflammatory cells in the corneal specimens of patients with ICE syndrome suggests a viral etiology. In a study using polymerase chain reaction techniques, 16 of 25 corneas from patients with ICE syndrome and 4 of 6 patients with herpetic keratitis were positive for herpes simplex virus. Glaucoma associated with ICE syndrome is believed to be due to trabecular meshwork obstruction caused by peripheral anterior synechiae or, less commonly, an abnormal cellular membrane. FrequencyUnited StatesThe frequency of glaucoma associated with increased EVP or with ICE syndrome is unknown. Glaucoma has been reported to occur in 30% of patients with Sturge-Weber syndrome, 5% of patients with thyroid ophthalmopathy, 11.6% of patients with scleritis, and 4% of patients with episcleritis. Mortality/Morbidity
Sex
Age
CLINICALHistory
Physical
Causes
DIFFERENTIALSGlaucoma, Low Tension
|
| Drug Name | Timolol 0.25%, 0.5% (Timoptic, Timoptic XE, Blocadren) |
|---|---|
| Description | May reduce elevated and normal IOP, with or without glaucoma, by reducing production of aqueous humor or by outflow. |
| Adult Dose | Timoptic: 1 gtt bid Timoptic XE: 1 gtt qd |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; cardiac disease; low blood pressure; low pulse rate; pulmonary disease (eg, asthma, COPD); history of depression; history of hyperlipidemia |
| Interactions | May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May exacerbate or precipitate heart block, asthma, COPD, and mental changes (especially in elderly persons); may alter blood lipid profile |
| Drug Name | Levobunolol 0.25% or 0.5% (AK Beta, Betagan) |
|---|---|
| Description | Nonselective beta-adrenergic blocking agent that lowers IOP by reducing aqueous humor production and possibly increases outflow of aqueous humor. |
| Adult Dose | 1 gtt bid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; bronchial asthma; severe COPD; sinus bradycardia; second- and third-degree AV block; overt cardiac failure; cardiogenic shock |
| Interactions | May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May potentiate muscle weakness that is consistent with certain myasthenic symptoms (eg, diplopia, ptosis, generalized weakness); product may have sulfites, which may cause allergic-type reactions in certain susceptible persons |
| Drug Name | Metipranolol 0.3% (OptiPranolol) |
|---|---|
| Description | Beta-adrenergic blocker that has little or no intrinsic sympathomimetic effects and membrane-stabilizing activity. Has little local anesthetic activity. Reduces IOP by reducing production of aqueous humor. |
| Adult Dose | 1 gtt bid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; sinus tachycardia; cardiac failure; cardiogenic shock; second- and third-degree AV block |
| Interactions | May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May exacerbate or precipitate heart block, asthma, COPD, and mental changes (especially in elderly persons); may alter blood lipid profile |
| Drug Name | Carteolol 1.0% (Ocupress) |
|---|---|
| Description | Blocks beta 1- and beta 2-receptors and has mild intrinsic sympathomimetic effects. |
| Adult Dose | 1 gtt bid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; congestive heart failure; asthma; cardiac conduction defects; breastfeeding |
| Interactions | May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Product may have sulfites, which may cause allergic-type reactions in certain susceptible persons |
| Drug Name | Betaxolol 0.25% or 0.5% (Betoptic) |
|---|---|
| Description | Selectively blocks beta 1-adrenergic receptors with little or no effect on beta 2-receptors. Reduces IOP by reducing production of aqueous humor. |
| Adult Dose | 1 gtt bid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; bronchial asthma; severe COPD; sinus bradycardia; second- and third-degree AV block; overt cardiac failure; cardiogenic shock |
| Interactions | May have additive systemic effects if patient is already on systemic beta-blockers |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Beta-blockade may potentiate muscle weakness consistent with myasthenic symptoms; product may have sulfites, which may cause hypersensitivity reactions in susceptible persons |
Act to decrease aqueous humor formation.
| Drug Name | Brimonidine 0.2% (Alphagan) |
|---|---|
| Description | Selective alpha 2-receptor that reduces aqueous humor formation and increases uveoscleral outflow. |
| Adult Dose | 1 gtt tid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; patients receiving MAOIs |
| Interactions | Coadministration with topical beta-blockers may further decrease IOP; tricyclic antidepressants may decrease effects of brimonidine; CNS depressants (eg, barbiturates, opiates, sedatives) may potentiate effects of brimonidine |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | May exacerbate or precipitate ocular irritation, topical sensitivity, vasovagal attack, and optic nerve ischemia in patients with advanced glaucomatous optic neuropathy |
| Drug Name | Apraclonidine 0.5% or 1% (Iopidine) |
|---|---|
| Description | Reduces elevated, as well as normal, IOP whether or not accompanied by glaucoma. A relatively selective alpha-adrenergic agonist that does not have significant local anesthetic activity. Has minimal cardiovascular effects. |
| Adult Dose | 1 gtt tid prelaser and postlaser or surgery, short term |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; patients on MAOIs or have taken them in the past 14 d |
| Interactions | Monitor pulse and BP frequently when giving cardiovascular drugs; not for use concurrently with MAOIs |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May exacerbate or precipitate ocular irritation, topical sensitivity, vasovagal attack, and optic nerve ischemia in patients with advanced glaucomatous optic neuropathy |
Enzyme found in many tissues of the body, including the eye. Catalyzes a reversible reaction where carbon dioxide becomes hydrated and carbonic acid dehydrated. By slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport, it may inhibit CA in the ciliary processes of the eye. This effect decreases aqueous humor secretion, reducing IOP.
| Drug Name | Acetazolamide (Diamox, Diamox Sequels) |
|---|---|
| Description | Inhibits enzyme CA, reducing the rate of aqueous humor formation, which, in turn, reduces IOP. Used for adjunctive treatment of chronic simple (open angle) glaucoma and secondary glaucoma and preoperatively in acute angle-closure glaucoma when delay of surgery desired to lower IOP. |
| Adult Dose | 125 mg or 250 mg PO bid/qid or 5-10 mg/kg q6-8h or 500 mg SR cap bid |
| Pediatric Dose | 5 mg/kg PO q6h |
| Contraindications | Documented hypersensitivity; hepatic disease; severe renal disease; adrenocortical insufficiency; severe pulmonary obstruction |
| Interactions | Can decrease therapeutic levels of lithium and alter excretion of drugs (amphetamines, quinidine, phenobarbital, salicylates) by alkalinizing urine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May exacerbate or precipitate lethargy, depression, weight loss, acidosis, renal stones, and bone marrow suppression; patients with impaired hepatic function may go into coma; may cause substantial increase in blood glucose in some diabetic patients |
| Drug Name | Dorzolamide 2% (Trusopt) |
|---|---|
| Description | Used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one ophthalmic drug is being used, administer the drugs at least 10 min apart. Reversibly inhibits CA, reducing hydrogen ion secretion at renal tubule and increasing renal excretion of sodium, potassium bicarbonate, and water to decrease production of aqueous humor. |
| Adult Dose | 1 gtt tid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with high-dose salicylate therapy may increase toxicity; may have additive systemic effects if patient is already on oral CA inhibitors |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Local ocular adverse effects, primarily conjunctivitis and lid reactions, may occur with long-term administration of dorzolamide (discontinue therapy and evaluate patient before restarting therapy) |
| Drug Name | Methazolamide (Neptazane) |
|---|---|
| Description | Reduces aqueous humor formation by inhibiting enzyme CA, which results in decreased IOP. |
| Adult Dose | 25-50 mg PO bid/tid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | May increase toxicity of salicylate, digoxin; coadministration with other diuretics may induce hypokalemia; decreases effects of lithium and alters excretion of other drugs by alkalinizing urine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in respiratory acidosis and diabetes mellitus; impairs mental alertness and/or physical coordination; hematuria, glycosuria, polyuria, hepatic insufficiency, bone marrow suppression, thrombocytopenia/purpura, agranulocytosis, urticaria, pruritus, and rash may occur |
| Drug Name | Brinzolamide 1% (Azopt) |
|---|---|
| Description | Catalyzes reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid. May use concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, administer drugs at least 10 min apart. |
| Adult Dose | 1 gtt tid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | May have additive systemic effects if patient is already on oral CA inhibitors |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Local ocular adverse effects, primarily conjunctivitis and lid reactions, may occur with long-term administration (discontinue therapy and evaluate patient before restarting therapy) |
These agents may decrease intraocular pressure by increasing the outflow of aqueous humor.
They are administered once per day (except for unoprostone, which is administered twice daily). Potential adverse effects of these medications are similar to latanoprost (eg, eyelash growth, increased iris pigmentation). These agents are considered by some glaucoma specialists as first-line agents for glaucoma, mainly because of the lack of systemic adverse effects.
| Drug Name | Bimatoprost ophthalmic solution (Lumigan) |
|---|---|
| Description | A prostamide analogue with ocular hypotensive activity. Mimics the IOP-lowering activity of prostamides via the prostamide pathway. Used to reduce IOP in open-angle glaucoma or ocular hypertension. |
| Adult Dose | 1 gtt of 0.03% solution in affected eye(s) hs; not to exceed 1 dose/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses |
| Drug Name | Travoprost ophthalmic solution (Travatan) |
|---|---|
| Description | Prostaglandin F2-alpha analog. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. Used to treat open-angle glaucoma or ocular hypertension. |
| Adult Dose | 1 gtt in affected eye(s) hs; not to exceed 1 dose/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; pregnancy |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Commonly causes ocular hyperemia; may cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses |
| Drug Name | Unoprostone ophthalmic solution (Rescula) |
|---|---|
| Description | Prostaglandin F2-alpha analog. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. Used to treat open-angle glaucoma or ocular hypertension. |
| Adult Dose | 1 gtt in affected eye(s) bid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Commonly causes ocular hyperemia; may cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses |
Article Last Updated: Mar 8, 2007